1
Return

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age

delete2026-07-10
delete0
delete
OA
AI
M
Mihir Desai *
G
Gilberto Jimenez
P
Priyantha Wijewardane
L
Lan Lan
S
Shraddha Mehta
F
Frances Priddy
DOI：10.1093/infdis/jiag350delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals aged ≥60 years and those aged 18-59 years at high-risk of severe RSV disease. Protection offered by a single dose of an RSV vaccine is not expected to be lifelong, and data on revaccination are needed.

Journal

T
The Journal of Infectious Diseases
IF:
0
Papers:
242
Citations:
0

Organization

B
baptist health
Scholars:
10
Papers: 10
Citations: 0
S
spotlight research center
Scholars:
2
Papers: 1
Citations: 0
M
Moderna, Inc.
Scholars:
104
Papers: 16
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers